DelveInsight’s, “Advanced Endometrial Cancer Pipeline Insight 2024” report provides comprehensive insights about 25+ Advanced Endometrial Cancer companies and 25+ pipeline drugs in the Advanced Endometrial Cancer pipeline landscape. It covers the Advanced Endometrial Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Endometrial Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Advanced Endometrial Cancer Pipeline Report
- DelveInsight’s Advanced Endometrial Cancer pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Advanced Endometrial Cancer treatment.
- The leading companies working in the Advanced Endometrial Cancer market include Incyte Corporation, Byondis B.V., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Ability Pharmaceuticals SL, Zymeworks Inc., AstraZeneca, Eli Lilly and Company, Pfizer, Karyopharm Therapeutics, Genentech, Eli Lilly and Company, Genentech Inc., NETRIS Pharma, Five Prime Therapeutics, Inc., Millennium Pharmaceuticals, Inc., Novartis Oncology, Takeda, Mundipharma-EDO GmbH, Zai Lab (Shanghai) Co., Ltd., Haihe Biopharma Co., Ltd., Xencor, Compugen Ltd, Checkpoint Therapeutics Inc., Celon Pharma SA, Dragonfly Therapeutics, and others.
- Promising Advanced Endometrial Cancer pipeline therapies in the various stages of development include Envafolimab+Lenvatinib, BKM120, TQB2450 injection, Anlotinib Hydrochloride Capsule, Carboplatin Injection, Pembrolizumab, Lenvatinib, Paclitaxel, Doxorubicin, Arzoxifene Hydrochloride, and others.
- On January 2023, 3D Medicines (Sichuan) Co. Ltd announced a study of Phase 2 clinical trials for Envafolimab. This is an open-label, multi-center, multi-corhort Phase II study of Envafolimab alone or with Lenvatinib in patients with advanced endometrial cancer. The primary objective is to evaluate objective response rate of envafolimab alone or with lenvatinib.
- On June 2023, Eisai Inc. announced a study of Phase 2 clinical trials for Lenvatinib. To assess the objective response rate (ORR: complete response + partial response [CR+ PR]) of E7080 in subjects with unresectable endometrial cancer and disease progression following platinum-based, first-line chemotherapy.
- On July 2023, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. announced a study of Phase 2 clinical trials for TQB2450 injection and Docetaxel injection. This study plans to enroll 69 subjects of endometrial cancer and 5-10 subjects of sarcoma of uterus. The experimental set is divided into lead-in trial and formal trial. The lead-in trial includes 9 subjects to observe the safety of the combination and determine the dosage of anlotinib dihydrochloride capsules before the formal phase.
- On August 2023, Tesaro Inc. announced a study of Phase 3 clinical trials for Dostarlimab, Carboplatin, Paclitaxel, and Niraparib. This is a 2 part study. Part 1 is to evaluate the efficacy and safety of dostarlimab plus carboplatin-paclitaxel followed by dostarlimab versus placebo plus carboplatin-paclitaxel followed by placebo; and Part 2 is to evaluate the efficacy and safety of dostarlimab plus carboplatin-paclitaxel followed by dostarlimab plus niraparib versus placebo plus carboplatin-paclitaxel followed by placebo in participants with recurrent or primary advanced (Stage III or IV) endometrial cancer.
Request a sample and discover the recent advances in Advanced Endometrial Cancer Treatment Drugs @ Advanced Endometrial Cancer Infection Pipeline Report
The Advanced Endometrial Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Advanced Endometrial Cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Advanced Endometrial Cancer clinical trial landscape.
Advanced Endometrial Cancer Overview
Metastatic or advanced uterine (endometrial) cancer is a type of cancer that originated in the lining of the uterus (endometrium) and has spread to distant areas of the body. In general, uterine cancer can metastasize to the rectum or bladder.
Find out more about Advanced Endometrial Cancer Treatment Landscape @ Drugs for Advanced Endometrial Cancer Treatment
Advanced Endometrial Cancer Emerging Drugs Profile
- Retifanlimab: Incyte Corporation
- Trastuzumab duocarmazine (SYD985): Byondis
Advanced Endometrial Cancer Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing the therapies for Advanced Endometrial Cancer. The Advanced Endometrial Cancer companies which have their Advanced Endometrial Cancer drug candidates in the most advanced stage, i.e. phase II include, Incyte Corporation.
Learn more about the emerging Advanced Endometrial Cancer Pipeline Therapies @ Advanced Endometrial Cancer Clinical Trials Assessment
Scope of the Advanced Endometrial Cancer Pipeline Report
- Coverage- Global
- Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Advanced Endometrial Cancer- Incyte Corporation, Byondis B.V., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Ability Pharmaceuticals SL, Zymeworks Inc., AstraZeneca, Eli Lilly and Company, Pfizer, Karyopharm Therapeutics, Genentech, Eli Lilly and Company, Genentech Inc., NETRIS Pharma, Five Prime Therapeutics, Inc., Millennium Pharmaceuticals, Inc., Novartis Oncology, Takeda, Mundipharma-EDO GmbH, Zai Lab (Shanghai) Co., Ltd., Haihe Biopharma Co., Ltd., Xencor, Compugen Ltd, Checkpoint Therapeutics Inc., Celon Pharma SA, Dragonfly Therapeutics, and others.
- Advanced Endometrial Cancer pipeline therapies- Envafolimab+Lenvatinib, BKM120, TQB2450 injection, Anlotinib Hydrochloride Capsule, Carboplatin Injection, Pembrolizumab, Lenvatinib, Paclitaxel, Doxorubicin, Arzoxifene Hydrochloride, and others.
Dive deep into rich insights for new drugs for Advanced Endometrial Cancer treatment, Visit @ Advanced Endometrial Cancer Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Advanced Endometrial Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Advanced Endometrial Cancer – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Selinexor: Karyopharm Therapeutics
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Retifanlimab: Incyte Corporation
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Alsevalimab: Five Prime Therapeutics
- Drug profiles in the detailed report…..
- Inactive Products
- Advanced Endometrial Cancer Key Companies
- Advanced Endometrial Cancer Key Products
- Advanced Endometrial Cancer- Unmet Needs
- Advanced Endometrial Cancer- Market Drivers and Barriers
- Advanced Endometrial Cancer- Future Perspectives and Conclusion
- Advanced Endometrial Cancer Analyst Views
- Advanced Endometrial Cancer Key Companies
- Appendix
For further information on the Advanced Endometrial Cancer pipeline therapeutics, reach out to Advanced Endometrial Cancer Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services
